Solve Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$321M
- Investors
-
15
Solve Therapeutics General Information
Description
Operator of a drug development platform intended to develop novel antibody-drug conjugates. The company is developing bispecific therapeutics engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics, enabling medical professionals to help patients improve their lives and fulfill some unmet needs.
Contact Information
Website
www.solvetx.comCorporate Office
- 1025 Alameda De Las Pulgas
- Suite 122
- Belmont, CA 94002
- United States
Corporate Office
- 1025 Alameda De Las Pulgas
- Suite 122
- Belmont, CA 94002
- United States
Solve Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 17-Nov-2025 | $321M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC | 17-Dec-2021 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2021 | Completed | Startup |
Solve Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Solve Therapeutics Patents
Solve Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217653-A1 | Drug-linker compounds | Pending | 09-Apr-2025 | ||
| WO-2026178013-A1 | Conjugates and uses thereof | Pending | 18-Feb-2025 | ||
| WO-2026178014-A1 | Conjugates and uses thereof | Pending | 18-Feb-2025 | ||
| WO-2026174205-A1 | Adozelesin based antibody drug conjugates and uses thereof | Pending | 14-Feb-2025 | ||
| WO-2026173867-A1 | Conjugates and uses thereof | Pending | 12-Feb-2025 | A61K47/6889 |
Solve Therapeutics Signals
Solve Therapeutics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Ally Bridge Group | Growth/Expansion | Minority | ||
| AyurMaya Capital | PE/Buyout | Minority | ||
| Balyasny Asset Management | Hedge Fund | Minority |
Solve Therapeutics Acquisitions (1)
Solve Therapeutics’s most recent deal was a Merger/Acquisition with Cereius. The deal was made on 22-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cereius | 22-Jun-2023 | Merger/Acquisition | Drug Discovery |
Solve Therapeutics FAQs
-
When was Solve Therapeutics founded?
Solve Therapeutics was founded in 2021.
-
Where is Solve Therapeutics headquartered?
Solve Therapeutics is headquartered in Belmont, CA.
-
What is the size of Solve Therapeutics?
Solve Therapeutics has 33 total employees.
-
What industry is Solve Therapeutics in?
Solve Therapeutics’s primary industry is Drug Discovery.
-
Is Solve Therapeutics a private or public company?
Solve Therapeutics is a Private company.
-
What is the current valuation of Solve Therapeutics?
The current valuation of Solve Therapeutics is .
-
What is Solve Therapeutics’s current revenue?
The current revenue for Solve Therapeutics is .
-
How much funding has Solve Therapeutics raised over time?
Solve Therapeutics has raised $385M.
-
Who are Solve Therapeutics’s investors?
Abingworth, Alexandria Venture Investments, Ally Bridge Group, AyurMaya Capital, and Balyasny Asset Management are 5 of 15 investors who have invested in Solve Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process